Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Enriched FAK Activity Protects Cardiomyocytes from Heart Attack Damage

By BiotechDaily International staff writers
Posted on 22 Mar 2012
Print article
Cardiovascular disease researchers have identified a protein in cardiomyocytes that when expressed at high levels protects heart cells from damage caused during myocardial infarction due to the sudden loss of oxygen.

Investigators at the University of North Carolina (Chapel Hill, USA) had shown previously that deletion of the enzyme focal adhesion kinase (FAK) exacerbated myocyte death following heart attack. FAK is a highly conserved, cytosolic, protein-tyrosine kinase involved in cell-cell and cell-matrix interaction and responsible for formation of the focal adhesion complex. It is widely expressed throughout development.

In the current study, the investigators examined the effect of enriched FAK activity on cardiomyocytes during and after heart attack (ischemia/perfusion) in a mouse model. To this end, they created a line of mice genetically engineered to express a highly active form of FAK (SuperFAK) in their cardiomyocytes.

They reported in the March 1, 2012, online edition of the journal Arteriosclerosis, Thrombosis and Vascular Biology that FAK activity in unstressed transgenic hearts was modestly elevated, but this had no discernible effect on anabolic heart growth or cardiac function. On the other hand, SuperFAK hearts exhibited a dramatic increase in FAK activity and a reduction in myocyte apoptosis and infarct size 24 to 72 hours following ischemia/perfusion.

Mechanistic studies revealed that elevated FAK activity protected cardiomyocytes from ischemia/perfusion-induced apoptosis by enhancing nuclear factor-kappaB (NF-kappaB)-dependent survival signaling during the early period of reperfusion (30 and 60 minutes). Moreover, adenoviral-mediated expression of SuperFAK in cultured cardiomyocytes attenuated H2O2 or hypoxia/reoxygenation-induced apoptosis. Blockade of the NF-kappaB pathway using a pharmacological inhibitor or small interfering RNAs completely abolished the beneficial effect of SuperFAK.

"This study shows that we can enhance existing cell survival pathways to protect heart cells during a heart attack," said senior author Dr. Joan Taylor, associate professor of pathology and laboratory medicine at the University of North Carolina. "We thought if we could activate FAK to a greater extent, then we could better protect those heart cells."

"I think folks could use this idea to exploit mutations in other molecules - by thinking about how to modify the protein so that it can be under natural controls," said Dr. Taylor. "Negative feedback loops are important because they "reset" the system."

Related Links:

University of North Carolina


Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.